FDA 483 - Serum Institute of India Pvt. Ltd. - April 19, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspection of Serum Institute of India Pvt. Ltd. in Manjari Bk., Pune, revealed significant deficiencies in their manufacturing operations. Key issues included widespread good documentation practices and data integrity failures, inadequate process validation, and a lack of robust systems for deviation reporting, investigations, and timely corrective actions. These findings indicate serious concerns regarding the firm's quality control and compliance with regulatory standards.
ID · 3a35200c-1d8e-412d-91fa-012ff9fbaa90